Phenotypic characterization of TAMs
. | Control cells in medium alone (range) . | . | TAMs (range) . | . | Cells exposed to GM-CSF + IL-4 (range) . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Surface marker* . | 3 d . | 5 d . | 3 d . | 5 d . | 3 d . | 5 d . | |||
| CD1a | |||||||||
| % + | 9 (2-19) | 13 (5-19) | 33† (9-75) | 40† (3-53) | 32† (11-56) | 50† (20-83) | |||
| MFI | 21 (16-30) | 19 (16-29) | 36 (14-71) | 26 (12-50) | 142† (20-241) | 316† (100-755) | |||
| CD14 | |||||||||
| % + | 53 (23-78) | 51 (26-80) | 92†,‡ (57-98) | 89†,‡ (79-97) | 5† (4-22) | 2† (1-6) | |||
| MFI | 103 (23-152) | 89 (35-166) | 343†,‡ (40-584) | 180† (36-446) | 271 (13-388) | 224 (8-450) | |||
| CD83 | |||||||||
| % + | 19‡ (12-23) | 25‡ (18-69) | 10‡ (5-49) | 20‡ (3-51) | 59 (27-67) | 51 (40-66) | |||
| MFI | 16 (11-23) | 16 (11-72) | 17 (11-33) | 13 (10-38) | 19 (14-26) | 19 (17-27) | |||
| MR/CD206 | |||||||||
| % + | 68 (21-85) | 66 (17-80) | 86 (49-99) | 92† (40-99) | 95† (90-99) | 96† (92-97) | |||
| MFI | 54 (29-156) | 50 (22-96) | 115 (29-209) | 164† (29-305) | 110 (47-265) | 15† (53-293) | |||
| HLA-DR | |||||||||
| % + | 54‡ (31-94) | 33‡ (13-69) | 67‡ (52-96) | 69‡ (15-97) | 99 (98-100) | 99 (96-100) | |||
| MFI | 143‡ (33-252) | 77‡ (25-445) | 128‡ (84-238) | 128‡ (33-281) | 423 (215-979) | 433 (291-725) | |||
. | Control cells in medium alone (range) . | . | TAMs (range) . | . | Cells exposed to GM-CSF + IL-4 (range) . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Surface marker* . | 3 d . | 5 d . | 3 d . | 5 d . | 3 d . | 5 d . | |||
| CD1a | |||||||||
| % + | 9 (2-19) | 13 (5-19) | 33† (9-75) | 40† (3-53) | 32† (11-56) | 50† (20-83) | |||
| MFI | 21 (16-30) | 19 (16-29) | 36 (14-71) | 26 (12-50) | 142† (20-241) | 316† (100-755) | |||
| CD14 | |||||||||
| % + | 53 (23-78) | 51 (26-80) | 92†,‡ (57-98) | 89†,‡ (79-97) | 5† (4-22) | 2† (1-6) | |||
| MFI | 103 (23-152) | 89 (35-166) | 343†,‡ (40-584) | 180† (36-446) | 271 (13-388) | 224 (8-450) | |||
| CD83 | |||||||||
| % + | 19‡ (12-23) | 25‡ (18-69) | 10‡ (5-49) | 20‡ (3-51) | 59 (27-67) | 51 (40-66) | |||
| MFI | 16 (11-23) | 16 (11-72) | 17 (11-33) | 13 (10-38) | 19 (14-26) | 19 (17-27) | |||
| MR/CD206 | |||||||||
| % + | 68 (21-85) | 66 (17-80) | 86 (49-99) | 92† (40-99) | 95† (90-99) | 96† (92-97) | |||
| MFI | 54 (29-156) | 50 (22-96) | 115 (29-209) | 164† (29-305) | 110 (47-265) | 15† (53-293) | |||
| HLA-DR | |||||||||
| % + | 54‡ (31-94) | 33‡ (13-69) | 67‡ (52-96) | 69‡ (15-97) | 99 (98-100) | 99 (96-100) | |||
| MFI | 143‡ (33-252) | 77‡ (25-445) | 128‡ (84-238) | 128‡ (33-281) | 423 (215-979) | 433 (291-725) | |||
Purified CD14+ monocytes were exposed to either 100 nM Trx80 (to produce TAMs), GM-CSF + IL-4, or medium alone and cultured for 3 and 5 days in ultralow attachment plates.
The proportion of positive cells (% +) and the mean fluorescence index (MFI) were determined by flow cytometry. The data presented are medians and ranges of the values obtained with CD14+ monocytes from 8 different blood donors during the periods of incubation indicated.
P < .05 compared with cells cultured in medium alone as analyzed by using the nonparametric Wilcoxon matched-pairs test.
P < .05 compared with cells exposed to GM-CSF + IL-4 as analyzed by using the nonparametric Wilcoxon matched-pairs test.